Investor Relations

Esperion Therapeutics, Inc. is an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers.

Esperion Therapeutics is a publicly traded company (since 2013) and is listed on the NASDAQ Global Select Market under the symbol ESPR.

Esperion Therapeutics (NASDAQ: ESPR) 4:00 PM ET on Feb 27, 2015
Last Price Change Open Day High 52-Week High
3.87  down   (5.835%) 66.18 66.42 70.87
Volume Previous Close Day Low 52-Week Low
347,500 66.32 62.41 12.75

View all »   RSSRecent Releases

Feb 26, 2015
Esperion Therapeutics to Provide Fourth Quarter and Full Year ETC-1002 Program Updates and Financial Results

Feb 2, 2015
Esperion Therapeutics Announces Removal of PPAR Partial Clinical Hold for ETC-1002

View all »Events & Presentations

Mar 5, 2015 at 4:30 PM ET
Esperion Therapeutics Q4 2014 Conference Call